Limits...
Higher minor hemoglobin A2 levels in multiple sclerosis patients correlate with lesser disease severity

View Article: PubMed Central - PubMed

ABSTRACT

Objective: To define whether minor adult hemoglobin A2 (HbA2, α2δ2) exerts any protective activity in multiple sclerosis (MS).

Methods: HbA2 levels were measured in 146 MS patients with high performance liquid chromatography and association with MS Severity Scores (MSSS) were determined. HbA2 associations with blood count parameters were also studied using blood counts evaluated on the same day of high performance liquid chromatography sampling. Routine biochemical parameters were also determined to rule out elusively influential factors, such as anemia and thyroid disorders.

Results: HbA2 levels negatively correlated with MSSS (Spearman correlation, R: −0.186, P=0.025). Exclusion of confounding factors with a generalized linear model revealed an even stronger negative correlation between HbA2 and MSSS (P<0.001). HbA2 positively correlated with red blood cells (RBCs) (R=0.350, P<0.001) and in turn, RBCs negatively correlated with MSSS (R=−0.180, P=0.031). Average HbA2 levels were highest among patients treated with interferon β1a.

Conclusion: RBC fragility is increased in MS, and recent data suggest that circulating free Hb contributes to neural injury in MS. HbA2 and its oxidative denaturation product hemichrome A2 enhance RBC membrane stability to a greater extent than do major HbA or hemichrome A. Reductions in ischemic cerebrovascular vascular events are reported in β-thalassemia carriers and HbA2 levels are considerably higher in this population. Episodic declines of cerebral blood flow were shown in bipolar disorder, and we have recently shown a protective role of HbA2 against postpartum episodes in females with bipolar disorder. HbA2’s erythroprotective functions may reduce free Hb and long-term neural injury in MS.

No MeSH data available.


Related in: MedlinePlus

Box plot graph depicting median HbA2 values in different treatment groups.Notes: A reference line was drawn to represent the median HbA2 level in the whole study group. Treatment groups including <12 patients were omitted. MS patients treated with IFN-β1a had prominently higher levels of HbA2 in comparison to those treated with glatiramer acetate (P=0.002).Abbreviations: HbA2, hemoglobin A2; IFN-β1, interferon-β1; MS, multiple sclerosis.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4998019&req=5

f1-ndt-12-2033: Box plot graph depicting median HbA2 values in different treatment groups.Notes: A reference line was drawn to represent the median HbA2 level in the whole study group. Treatment groups including <12 patients were omitted. MS patients treated with IFN-β1a had prominently higher levels of HbA2 in comparison to those treated with glatiramer acetate (P=0.002).Abbreviations: HbA2, hemoglobin A2; IFN-β1, interferon-β1; MS, multiple sclerosis.

Mentions: Figure 1 is a box plot graph depicting median HbA2 values in different treatment groups. Groups including <12 patients were omitted. Kruskal–Wallis test revealed a significant difference in HbA2 levels between the five different treatment groups (P=0.033). Bonferroni correction of the Mann–Whitney U-test results demonstrated that MS patients treated with interferon (IFN)-β1a had prominently higher levels of HbA2 in comparison to those treated with glatiramer acetate (P=0.002). No difference was seen between the other drug regime or the untreated group (P>0.05).


Higher minor hemoglobin A2 levels in multiple sclerosis patients correlate with lesser disease severity
Box plot graph depicting median HbA2 values in different treatment groups.Notes: A reference line was drawn to represent the median HbA2 level in the whole study group. Treatment groups including <12 patients were omitted. MS patients treated with IFN-β1a had prominently higher levels of HbA2 in comparison to those treated with glatiramer acetate (P=0.002).Abbreviations: HbA2, hemoglobin A2; IFN-β1, interferon-β1; MS, multiple sclerosis.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4998019&req=5

f1-ndt-12-2033: Box plot graph depicting median HbA2 values in different treatment groups.Notes: A reference line was drawn to represent the median HbA2 level in the whole study group. Treatment groups including <12 patients were omitted. MS patients treated with IFN-β1a had prominently higher levels of HbA2 in comparison to those treated with glatiramer acetate (P=0.002).Abbreviations: HbA2, hemoglobin A2; IFN-β1, interferon-β1; MS, multiple sclerosis.
Mentions: Figure 1 is a box plot graph depicting median HbA2 values in different treatment groups. Groups including <12 patients were omitted. Kruskal–Wallis test revealed a significant difference in HbA2 levels between the five different treatment groups (P=0.033). Bonferroni correction of the Mann–Whitney U-test results demonstrated that MS patients treated with interferon (IFN)-β1a had prominently higher levels of HbA2 in comparison to those treated with glatiramer acetate (P=0.002). No difference was seen between the other drug regime or the untreated group (P>0.05).

View Article: PubMed Central - PubMed

ABSTRACT

Objective: To define whether minor adult hemoglobin A2 (HbA2, &alpha;2&delta;2) exerts any protective activity in multiple sclerosis (MS).

Methods: HbA2 levels were measured in 146 MS patients with high performance liquid chromatography and association with MS Severity Scores (MSSS) were determined. HbA2 associations with blood count parameters were also studied using blood counts evaluated on the same day of high performance liquid chromatography sampling. Routine biochemical parameters were also determined to rule out elusively influential factors, such as anemia and thyroid disorders.

Results: HbA2 levels negatively correlated with MSSS (Spearman correlation, R: &minus;0.186, P=0.025). Exclusion of confounding factors with a generalized linear model revealed an even stronger negative correlation between HbA2 and MSSS (P&lt;0.001). HbA2 positively correlated with red blood cells (RBCs) (R=0.350, P&lt;0.001) and in turn, RBCs negatively correlated with MSSS (R=&minus;0.180, P=0.031). Average HbA2 levels were highest among patients treated with interferon &beta;1a.

Conclusion: RBC fragility is increased in MS, and recent data suggest that circulating free Hb contributes to neural injury in MS. HbA2 and its oxidative denaturation product hemichrome A2 enhance RBC membrane stability to a greater extent than do major HbA or hemichrome A. Reductions in ischemic cerebrovascular vascular events are reported in &beta;-thalassemia carriers and HbA2 levels are considerably higher in this population. Episodic declines of cerebral blood flow were shown in bipolar disorder, and we have recently shown a protective role of HbA2 against postpartum episodes in females with bipolar disorder. HbA2&rsquo;s erythroprotective functions may reduce free Hb and long-term neural injury in MS.

No MeSH data available.


Related in: MedlinePlus